1. Home
  2. GO vs IOVA Comparison

GO vs IOVA Comparison

Compare GO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grocery Outlet Holding Corp.

GO

Grocery Outlet Holding Corp.

N/A

Current Price

$9.70

Market Cap

941.1M

ML Signal

N/A

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

N/A

Current Price

$2.37

Market Cap

881.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GO
IOVA
Founded
1946
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
941.1M
881.3M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
GO
IOVA
Price
$9.70
$2.37
Analyst Decision
Hold
Buy
Analyst Count
11
12
Target Price
$15.27
$10.45
AVG Volume (30 Days)
2.2M
12.7M
Earning Date
02-24-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,571,346,000.00
$250,425,000.00
Revenue This Year
$10.67
$60.71
Revenue Next Year
$5.13
$59.35
P/E Ratio
N/A
N/A
Revenue Growth
7.22
175.62
52 Week Low
$8.96
$1.64
52 Week High
$19.41
$6.16

Technical Indicators

Market Signals
Indicator
GO
IOVA
Relative Strength Index (RSI) 48.39 47.81
Support Level $9.06 $2.25
Resistance Level $9.63 $2.77
Average True Range (ATR) 0.43 0.22
MACD 0.06 -0.03
Stochastic Oscillator 65.94 31.01

Price Performance

Historical Comparison
GO
IOVA

About GO Grocery Outlet Holding Corp.

Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: